Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jacqueline Pesa, Charmi Patel, David Rotter, Eros Papademetriou, Ravi Potluri & Carmela Benson. (2021) Economic burden to commercial payers of young adults with schizophrenia in Colorado. Journal of Medical Economics 24:1, pages 1194-1203.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Janna Manjelievskaia, Tony B. Amos, Antoine C. El Khoury, Anna Vlahiotis, Ashley Cole & Paul Juneau. (2018) A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US. Journal of Medical Economics 21:12, pages 1221-1229.
Read now
Read now
Articles from other publishers (12)
Bryan Tanner, Paul Kurdyak & Claire de Oliveira. (2023) Adult Psychiatric Hospitalizations in Ontario, Canada Before and During the COVID-19 Pandemic. The Canadian Journal of Psychiatry 68:12, pages 925-932.
Crossref
Crossref
Shahrzad Bazargan-Hejazi, Anaheed Shirazi, David Hampton, Deyu Pan, Daniel Askharinam, Magda Shaheen, Gul Ebrahim & Denese Shervington. (2023) Examining racial disparity in psychotic disorders related ambulatory care visits: an observational study using national ambulatory medical care survey 2010–2015. BMC Psychiatry 23:1.
Crossref
Crossref
Laura MorrisonDee LinCarmela BensonIsabelle GhelerterMaude Vermette-LaformePatrick LefebvreDominic Pilon. (2023) Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. Journal of Managed Care & Specialty Pharmacy 29:2, pages 161-171.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up. Biomedicines 11:1, pages 42.
Crossref
Crossref
Alex Z. Fu, Jacqueline A. Pesa, Susan Lakey & Carmela Benson. (2022) Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry 22:1.
Crossref
Crossref
Zhijun Li, Xinwei Li, Mengdi Jin, Yang Liu, Yang He, Ningning Jia, Xingyao Cui, Yane Liu, Guoyan Hu & Qiong Yu. (2022) Identification of potential biomarkers and their correlation with immune infiltration cells in schizophrenia using combinative bioinformatics strategy. Psychiatry Research 314, pages 114658.
Crossref
Crossref
Samer El Hayek, Ghida Kassir, Raghid Charara, Francois Genadry, Alaeddine El Alayli & Joseph El-Khoury. (2022) Correlates of unscheduled and emergency clinical contact in a cohort of patients treated for psychosis. Psychiatry Research Communications 2:1, pages 100024.
Crossref
Crossref
Wei Zheng, Wen-Long Jiang, Xun Zhang, Dong-Bin Cai, Jia-Wei Sun, Fei Yin, Peng-Cheng Ren, Min Zhao, Hua-Wang Wu, Ying-Qiang Xiang, Wan-Nian Liang & Wei Zheng. (2021) Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies. Psychiatric Quarterly 93:1, pages 137-149.
Crossref
Crossref
Ethan Chen, Shahrzad Bazargan-Hejazi, Chizobam Ani, David Hindman, Deyu Pan, Gul Ebrahim, Anaheed Shirazi & Jim E. Banta. (2021) Schizophrenia hospitalization in the US 2005–2014. Medicine 100:15, pages e25206.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller & Paul Bergmans. (2020) Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Therapeutic Advances in Psychopharmacology 10, pages 204512532098150.
Crossref
Crossref
Barbara J. Limandri. (2019) Long-Acting Injectable Antipsychotic Medications: Why Aren't They Used as Often as Oral Formulations?. Journal of Psychosocial Nursing and Mental Health Services 57:3, pages 7-10.
Crossref
Crossref